Chemours Co (CC) Stock Analysis and Metrics

Chemours

NYSE: CC

$17.23 ▼ -0.24 (-1.40%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.60 Bn

P/E-8.43

P/S0.45

Div. Yield0.02

ROIC (Qtr)-0.01

Total Debt (Qtr)4.14 Bn

Revenue Growth (1y) (Qtr)0.95

Add ratio to table…

About

The Chemours Company is a leading global provider of performance chemicals that serve as key inputs in a variety of end-products and industrial processes across multiple sectors. The company delivers customized solutions through its portfolio of industrial and specialty chemical products serving markets such as refrigeration and air conditioning, paints and coatings, plastics, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Its principal products include refrigerants, titanium dioxide (TiO₂) pigment, and industrial fluoropolymer resins. The Chemours Company operates 28 major production facilities in eight countries and serves approximately 2,400 customers across about 110 countries.

The company generates revenue primarily through the sale of its performance chemical products, including refrigerants, thermal management solutions, propellants, blowing agents, specialty solvents, TiO₂ pigment, and high-end polymers and advanced materials under brands such as Opteon™, Ti-Pure™, Teflon™, Viton™, Krytox™, and Nafion™. These products are sold to a diverse base of industrial and commercial customers who rely on them for critical functionalities in their manufacturing processes and end products. Revenue is derived from both direct sales and distribution channels, with contracts ranging from spot-pricing arrangements to medium- and long-term agreements. The company's sales are not materially dependent on any single customer, with no individual customer representing more than 10% of consolidated net sales as of December 31, 2025.

The Chemours Company operates through the following three reportable segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.

• The Thermal & Specialized Solutions segment is a leading global provider of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. It has maintained a leading position in the refrigerants market since the commercial introduction of Freon™ in 1930 and is a leader in developing sustainable technologies like Opteon™, a line of low global warming potential (GWP) hydrofluoroolefin (HFO) refrigerants and specialty fluids. This segment serves approximately 800 customers and distributors globally and experienced seasonal demand patterns with higher sales in the first half of the year due to air conditioning demand in the northern hemisphere.

• The Titanium Technologies segment is a leading global manufacturer of TiO₂ pigment, sold under the Ti-Pure™ brand, used to deliver whiteness, brightness, opacity, durability, and protection in applications such as architectural and industrial coatings, plastic packaging, laminated paper, and coated paperboard. It operates three TiO₂ production facilities in the U. S. and Mexico, with a nameplate capacity of approximately 1.1 million metric tons per year, and operates mineral sands mines and separation facilities in Florida and Georgia. The segment serves approximately 500 customers globally, with its 10 largest customers accounting for over 44% of segment net sales in 2025, and one customer representing over 20% of segment net sales.

• The Advanced Performance Materials segment is a leading global provider of high-end polymers and advanced materials that deliver unique attributes including chemical inertness, thermal stability, low friction, weather and corrosion resistance, and electrical insulation. Its product portfolio includes specialty solutions, membranes, industrial resins, and coatings sold under the Teflon™, Viton™, Krytox™, and Nafion™ brand names. This segment serves approximately 900 customers and distributors globally, serves markets such as consumer electronics, semiconductors, transportation, energy, oil and gas, defense, and medical, and experienced historically lower sales in the fourth quarter due to planned maintenance activities.

The Chemours Company holds a strong position within the performance chemicals industry, leveraging its leadership in fluorine chemistry and materials science, broad operational scale, applications development capabilities, and deep customer relationships. In Thermal & Specialized Solutions, it competes against companies such as Solstice Advanced Materials, Arkema S. A., Orbia, Daikin Industries Ltd., and Chinese F-gas producers. In Titanium Technologies, its major competitors include Tronox Holdings plc, LB Group Co. Ltd., Kronos Worldwide Inc., and INEOS AG. In Advanced Performance Materials, key competitors are Daikin Industries Ltd., Syensqo S. A., AGC Inc., Gujarat Fluorochemicals Limited, and Dongyue Group Co., Ltd. The company's competitive advantages stem from its innovation and technical expertise, ability to operate complex manufacturing sites safely, long-term customer relationships based on trust and reliability, and its skilled workforce.

The Chemours Company serves a diverse customer base across its three segments, including approximately 800 customers in Thermal & Specialized Solutions, 500 in Titanium Technologies, and 900 in Advanced Performance Materials, with many relationships spanning decades. Its customers are typically leaders in their respective industries and include producers of decorative and industrial coatings, automotive and industrial coatings, polyolefin master batches, PVC, engineering polymers, laminate paper, coated paper and paperboard, semiconductor manufacturers, battery and fuel cell producers, aerospace and defense contractors, and operators in oil and gas, transportation, and data center sectors. The company's sales are not materially dependent on any single customer, with no individual customer exceeding 10% of consolidated net sales as of December 31, 2025.

Investment Thesis

▲ Bull case

Chemours demonstrates strong structural positioning in its Titanium Technologies business, with management explicitly stating they are 'clearly focused on our strategy of gaining share in the fair trade market' and maintaining 'being 1 of the lowest-cost chloride TiO2 producers worldwide' through disciplined cost control and supply chain optimization. The long-term chlorine supply contract signed for the DeLisle site starting in 2028 ensures reliable, value-accretive input costs, directly supporting their low-cost producer thesis and insulating them from sulfur-driven cost inflation affecting sulfate-based competitors. This operational resilience, combined with successful pricing actions (3% sequential increase in Q1, with another announced for April 1), allows Chemours to capture margin expansion even in volatile input cost environments, as evidenced by TT adjusted EBITDA exceeding expectations despite challenging market conditions. The company's ability to pass through cost increases while maintaining volume stability in key markets reflects a durable competitive advantage that the market may be underestimating amid broader TiO2 sector weakness.
The Advanced Performance Materials segment shows clear signs of sustainable recovery driven by high-value end markets, with management highlighting 'Performance Solutions order book is seeing particular strength in high-value data center and semiconductor markets' and noting 'demand remains strong in the semiconductor and data center end markets, which are driving orders for our Performance Solutions products.' This is further reinforced by the APM outlook calling for sequential net sales growth in the 'low to high 30% range' in Q2, primarily due to the resumption of normal operations at Washington Works, indicating that the prior quarter's weakness was largely transient and tied to specific operational disruptions rather than fundamental demand deterioration. The strong order velocity, described as 'a level that has not been experienced in the past several years,' suggests pent-up demand is being realized, positioning APM for meaningful earnings acceleration in the second half of 2026 as normalized operations translate into improved profitability, with EBITDA expected to reach the $30–40 million range by the back half of the year.
Chemours' balance sheet transformation represents an underappreciated catalyst, with management detailing proactive deleveraging efforts: 'we completed the sale of nearly all of our Kuan Yin properties ahead of schedule and promptly use the available proceeds to pay down a meaningful portion of our near-term debt,' followed by the $700 million refinancing in March that extended 2027 and 2028 unsecured notes to 2034. These actions have significantly reduced near-term maturities and enhanced financial flexibility, with the company targeting 'net leverage below 3x adjusted EBITDA' and anticipating 'net leverage ratio will be below 3.8x adjusted EBITDA by the end of the year.' The resulting interest expense savings—'approximately $9 million in interest expense savings to the company going forward annually by year-end'—combined with projected free cash flow generation of 'at least $100 million' in Q2 and full-year conversion now expected to be 'above 20%' provide substantial financial firepower for continued debt reduction, shareholder returns, or strategic investments, all of which are not fully reflected in current valuation multiples given the market's focus on near-term earnings volatility.

Chemours demonstrates strong structural positioning in its Titanium Technologies business, with management explicitly stating they are 'clearly focused on our strategy of gaining share in the fair trade market' and maintaining 'being 1 of the lowest-cost chloride TiO2 producers worldwide' through disciplined cost control and supply chain optimization. The long-term chlorine supply contract signed for the DeLisle site starting in 2028 ensures reliable, value-accretive input costs, directly supporting their low-cost producer thesis and insulating them from sulfur-driven cost inflation affecting sulfate-based competitors. This operational resilience, combined with successful pricing actions (3% sequential increase in Q1, with another announced for April 1), allows Chemours to capture margin expansion even in volatile input cost environments, as evidenced by TT adjusted EBITDA exceeding expectations despite challenging market conditions. The company's ability to pass through cost increases while maintaining volume stability in key markets reflects a durable competitive advantage that the market may be underestimating amid broader TiO2 sector weakness.
The Advanced Performance Materials segment shows clear signs of sustainable recovery driven by high-value end markets, with management highlighting 'Performance Solutions order book is seeing particular strength in high-value data center and semiconductor markets' and noting 'demand remains strong in the semiconductor and data center end markets, which are driving orders for our Performance Solutions products.' This is further reinforced by the APM outlook calling for sequential net sales growth in the 'low to high 30% range' in Q2, primarily due to the resumption of normal operations at Washington Works, indicating that the prior quarter's weakness was largely transient and tied to specific operational disruptions rather than fundamental demand deterioration. The strong order velocity, described as 'a level that has not been experienced in the past several years,' suggests pent-up demand is being realized, positioning APM for meaningful earnings acceleration in the second half of 2026 as normalized operations translate into improved profitability, with EBITDA expected to reach the $30–40 million range by the back half of the year.
Chemours' balance sheet transformation represents an underappreciated catalyst, with management detailing proactive deleveraging efforts: 'we completed the sale of nearly all of our Kuan Yin properties ahead of schedule and promptly use the available proceeds to pay down a meaningful portion of our near-term debt,' followed by the $700 million refinancing in March that extended 2027 and 2028 unsecured notes to 2034. These actions have significantly reduced near-term maturities and enhanced financial flexibility, with the company targeting 'net leverage below 3x adjusted EBITDA' and anticipating 'net leverage ratio will be below 3.8x adjusted EBITDA by the end of the year.' The resulting interest expense savings—'approximately $9 million in interest expense savings to the company going forward annually by year-end'—combined with projected free cash flow generation of 'at least $100 million' in Q2 and full-year conversion now expected to be 'above 20%' provide substantial financial firepower for continued debt reduction, shareholder returns, or strategic investments, all of which are not fully reflected in current valuation multiples given the market's focus on near-term earnings volatility.

▼ Bear case

Chemours faces persistent structural headwinds in its Titanium Technologies business that management downplays, particularly regarding volume trends in non-western markets where 'lower volumes and less favorable product mix in certain non-western markets offset these gains, resulting in reduced global volumes overall compared to the prior quarter.' While pricing discipline has supported net sales, the reliance on price increases to offset volume weakness—evident in the statement that 'net sales finished within our expectations due to disciplined global pricing execution' despite down-trending volumes—suggests a fragile top-line trajectory. The company's acknowledgment that 'we do not expect the same year-over-year double-digit top line growth for the remainder of 2026 as comparisons begin to reflect the regulatory-driven adoption under the U.S. AIM Act' reveals an impending growth deceleration in TSS that the market may not be fully pricing in, especially as the prior year's strong performance was fueled by temporary regulatory tailwinds rather than organic demand.
The Advanced Performance Materials segment's recovery remains fragile and contingent on operational normalization, with management admitting that 'first quarter sales were constrained by the Washington Works outage and the prior closure of the Advanced Materials SPS Capstone line,' which 'weighed meaningfully on sales and incremental costs, resulting in a $25 million headwind in adjusted EBITDA.' Although the business expects to return to a $30–40 million EBITDA range in the back half of the year, this implies only a modest recovery from severely depressed levels, and the outlook remains highly dependent on the successful ramp of Washington Works operations—any further delays or unresolved issues could perpetuate earnings weakness. Furthermore, while order book strength is noted in high-value end markets, the broader Advanced Materials portfolio serves 'industrial end markets that advanced materials generally serve remain weak,' indicating that the recovery is narrow and not yet broad-based, leaving APM vulnerable to any softening in semiconductor or data center spending cycles.
Chemours' balance sheet improvements, while notable, are partially offset by ongoing cash flow drags that management acknowledges but does not fully mitigate, particularly the tax implications from the Kuan Yin land sale that caused 'full year free cash flow conversion [to be] now expected to be above 20%, slightly lower than our prior guidance.' The company's admission that this reduction in free cash flow conversion is 'driven by one in land sale tax implications' reveals a significant and previously underappreciated cash outflow that directly impacts the funds available for debt reduction or shareholder returns. Furthermore, the reliance on asset sales to drive deleveraging—'we intend to use those proceeds to continue redeeming future debt maturities'—suggests a lack of sustainable internal cash flow generation, making the balance sheet improvement somewhat temporary and dependent on continued monetization of non-core assets rather than operational excellence, which increases financial risk if asset sale opportunities diminish or market conditions worsen.

Chemours faces persistent structural headwinds in its Titanium Technologies business that management downplays, particularly regarding volume trends in non-western markets where 'lower volumes and less favorable product mix in certain non-western markets offset these gains, resulting in reduced global volumes overall compared to the prior quarter.' While pricing discipline has supported net sales, the reliance on price increases to offset volume weakness—evident in the statement that 'net sales finished within our expectations due to disciplined global pricing execution' despite down-trending volumes—suggests a fragile top-line trajectory. The company's acknowledgment that 'we do not expect the same year-over-year double-digit top line growth for the remainder of 2026 as comparisons begin to reflect the regulatory-driven adoption under the U.S. AIM Act' reveals an impending growth deceleration in TSS that the market may not be fully pricing in, especially as the prior year's strong performance was fueled by temporary regulatory tailwinds rather than organic demand.
The Advanced Performance Materials segment's recovery remains fragile and contingent on operational normalization, with management admitting that 'first quarter sales were constrained by the Washington Works outage and the prior closure of the Advanced Materials SPS Capstone line,' which 'weighed meaningfully on sales and incremental costs, resulting in a $25 million headwind in adjusted EBITDA.' Although the business expects to return to a $30–40 million EBITDA range in the back half of the year, this implies only a modest recovery from severely depressed levels, and the outlook remains highly dependent on the successful ramp of Washington Works operations—any further delays or unresolved issues could perpetuate earnings weakness. Furthermore, while order book strength is noted in high-value end markets, the broader Advanced Materials portfolio serves 'industrial end markets that advanced materials generally serve remain weak,' indicating that the recovery is narrow and not yet broad-based, leaving APM vulnerable to any softening in semiconductor or data center spending cycles.
Chemours' balance sheet improvements, while notable, are partially offset by ongoing cash flow drags that management acknowledges but does not fully mitigate, particularly the tax implications from the Kuan Yin land sale that caused 'full year free cash flow conversion [to be] now expected to be above 20%, slightly lower than our prior guidance.' The company's admission that this reduction in free cash flow conversion is 'driven by one in land sale tax implications' reveals a significant and previously underappreciated cash outflow that directly impacts the funds available for debt reduction or shareholder returns. Furthermore, the reliance on asset sales to drive deleveraging—'we intend to use those proceeds to continue redeeming future debt maturities'—suggests a lack of sustainable internal cash flow generation, making the balance sheet improvement somewhat temporary and dependent on continued monetization of non-core assets rather than operational excellence, which increases financial risk if asset sale opportunities diminish or market conditions worsen.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password